Articles related to ACUTE LYMPHOBLASTIC LEUKEMIA (ALL)

Chemotherapy-free regimens for Ph+ ALL have shown complete response rates of 94-100% with minimal toxicity, potentially eliminating the need for stem cell transplant in many patients.

The combination of ponatinib and blinatumomab demonstrated a 95% complete response rate and 91% 3-year overall survival rate in patients with Ph-positive ALL.

Menin inhibitors, targeting the menin-KMT2A interaction, have demonstrated significant response rates in treating specific genotypes of AML and ALL, offering a new avenue for personalized leukemia therapy.

Over a 4-year period, 500 patients were distributed equally between the two regimens. Two-year OS, relapse rates, and non-relapse mortality were similar between the two regiments, indicating that the busulfan regimen is non-inferior to the traditional TBI regimen.

The hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone(hyper-CVAD) regimen has undergone many modifications to make administration more palatable and user-friendly for patients and physicians in community and academic settings, including refinements to avoid complications and reduce adverse events. Dr. Elias Jabbour of MD Anderson Cancer Center reviews a number of these modifications in this interview.

Overall, NGS-based MRD analysis in ALL seems to be especially helpful in patients with RQ-PCR+ MolNE and may help to discriminate true MRD from false positivity in this considerable and clinically important group.